TYSABRI: Natalizumab Has Benefits on Disability and Quality of Life in Patients With Relapsing MS: Presented at EFNS: "GLASGOW, UK -- September 11, 2006 -- Monotherapy with the alpha4 integrin antagonist natalizumab [TYSABRI] results in significant improvements in scores on health-related quality of life (QoL) questionnaires in patients with relapsing-remitting multiple sclerosis (MS), according to results of a substudy from a multicentre, randomised, double-blind, placebo-controlled, phase 3 clinical trial.

The findings were presented here on September 5th at the 10th Congress of the European Federation of Neurological Societies (EFNS) by Michael Hutchinson, MD, professor of neurology, department of neurology, St. Vincent's University Hospital, Dublin, Ireland, on behalf of the AFFIRM study investigators....."